| Aug 13 |
ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results
|
| Aug 13 |
Why Is Acelyrin, Inc. (SLRN) The Best New Penny Stock to Buy Now?
|
| Aug 6 |
ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024
|
| Jul 5 |
Here's Why We're Watching Acelyrin's (NASDAQ:SLRN) Cash Burn Situation
|
| Jun 5 |
ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024
|
| May 29 |
ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024
|
